Company intelligence / Profile preview

Cognition Therapeutics, Inc.

Purchase, New York, United Statescogrx.com ↗

Ownership: Public · CGTX
Employees: ~28
Development stage: Other

Overview

Zervimesine (CT1812) showed positive results in Phase 2 SHIMMER study for DLB with improvements across measures of behavior, function, cognition and movement. In the Phase 2 SHINE study for Alzheimer's disease, results showed a 39% slowing of decline favoring CT1812, though the 1.04-point difference between placebo and treatment groups was modest. The company is advancing zervimesine into late-stage clinical trials for both DLB and AD in 2025.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small moleculesOral therapeutics
Industry: Biotech

Drug pipeline

5 assets

zervimesine

4 more assets in the full pipeline.

Partnerships

Alzheimer's Clinical Trials Consortium (ACTC)

Financials

Market cap: $60.4M
Total revenue: $0
Enterprise value: $30.2M

Beyond the preview

Go deeper on Cognition Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognition Therapeutics, Inc..